ORBIMED ADVISORS LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.45B2026 Q3+ $45.7M options (notional, not included)
Positions124
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.48.7%

What Changed This Quarter?

33 new stocks bought: ADRX (8.8%), BRVE (4.5%), ETRA (1.4%) +3038 positions fully exited: DYN, CGON, BSX +35 Biggest add: TVTX +374.5% in shares Biggest trim: AZN -58.6% in shares

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.